Innoviva Current Ratio 2011-2025 | INVA
Innoviva current ratio from 2011 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Innoviva Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-06-30 | $0.65B | $0.25B | 2.64 |
| 2025-03-31 | $0.58B | $0.24B | 2.48 |
| 2024-12-31 | $0.55B | $0.24B | 2.35 |
| 2024-09-30 | $0.40B | $0.22B | 1.79 |
| 2024-06-30 | $0.36B | $0.03B | 12.70 |
| 2024-03-31 | $0.31B | $0.03B | 10.42 |
| 2023-12-31 | $0.34B | $0.04B | 9.03 |
| 2023-09-30 | $0.31B | $0.04B | 8.43 |
| 2023-06-30 | $0.32B | $0.04B | 8.21 |
| 2023-03-31 | $0.30B | $0.04B | 7.77 |
| 2022-12-31 | $0.44B | $0.14B | 3.29 |
| 2022-09-30 | $0.46B | $0.16B | 2.77 |
| 2022-06-30 | $0.40B | $0.13B | 3.18 |
| 2022-03-31 | $0.32B | $0.11B | 2.91 |
| 2021-12-31 | $0.31B | $0.01B | 54.02 |
| 2021-09-30 | $0.24B | $0.00B | 75.82 |
| 2021-06-30 | $0.15B | $0.01B | 27.60 |
| 2021-03-31 | $0.37B | $0.00B | 98.04 |
| 2020-12-31 | $0.34B | $0.01B | 55.98 |
| 2020-09-30 | $0.57B | $0.00B | 146.75 |
| 2020-06-30 | $0.50B | $0.01B | 92.39 |
| 2020-03-31 | $0.47B | $0.00B | 166.87 |
| 2019-12-31 | $0.43B | $0.01B | 80.29 |
| 2019-09-30 | $0.37B | $0.00B | 110.18 |
| 2019-06-30 | $0.32B | $0.01B | 42.50 |
| 2019-03-31 | $0.25B | $0.00B | 66.02 |
| 2018-12-31 | $0.20B | $0.01B | 34.92 |
| 2018-09-30 | $0.12B | $0.00B | 28.18 |
| 2018-06-30 | $0.18B | $0.01B | 26.36 |
| 2018-03-31 | $0.11B | $0.00B | 27.85 |
| 2017-12-31 | $0.20B | $0.04B | 5.77 |
| 2017-09-30 | $0.22B | $0.03B | 6.71 |
| 2017-06-30 | $0.20B | $0.03B | 7.31 |
| 2017-03-31 | $0.21B | $0.02B | 10.47 |
| 2016-12-31 | $0.20B | $0.02B | 9.88 |
| 2016-09-30 | $0.19B | $0.02B | 12.47 |
| 2016-06-30 | $0.19B | $0.02B | 13.02 |
| 2016-03-31 | $0.20B | $0.01B | 18.52 |
| 2015-12-31 | $0.21B | $0.01B | 15.89 |
| 2015-09-30 | $0.22B | $0.01B | 19.84 |
| 2015-06-30 | $0.24B | $0.01B | 19.97 |
| 2015-03-31 | $0.26B | $0.01B | 23.90 |
| 2014-12-31 | $0.25B | $0.01B | 18.33 |
| 2014-09-30 | $0.27B | $0.04B | 7.58 |
| 2014-06-30 | $0.35B | $0.05B | 7.06 |
| 2014-03-31 | $0.39B | $0.04B | 8.82 |
| 2013-12-31 | $0.48B | $0.08B | 5.73 |
| 2013-09-30 | $0.52B | $0.04B | 13.51 |
| 2013-06-30 | $0.46B | $0.04B | 11.83 |
| 2013-03-31 | $0.48B | $0.03B | 16.11 |
| 2012-12-31 | $0.26B | $0.03B | 8.71 |
| 2012-09-30 | $0.28B | $0.03B | 10.43 |
| 2012-06-30 | $0.30B | $0.03B | 11.77 |
| 2012-03-31 | $0.20B | $0.03B | 7.99 |
| 2011-12-31 | $0.25B | $0.05B | 5.38 |
| 2011-09-30 | $0.27B | $0.04B | 6.76 |
| 2011-06-30 | $0.29B | $0.04B | 8.20 |
| 2011-03-31 | $0.30B | $0.03B | 8.99 |
| 2010-12-31 | $0.32B | $0.04B | 7.90 |
| 2010-09-30 | $0.20B | $0.04B | 5.43 |
| 2010-06-30 | $0.22B | $0.04B | 6.01 |
| 2010-03-31 | $0.23B | $0.04B | 6.53 |
| 2009-12-31 | $0.16B | $0.04B | 4.16 |
| 2009-09-30 | $0.16B | $0.04B | 4.14 |
| 2009-06-30 | $0.18B | $0.04B | 4.57 |
| 2009-03-31 | $0.19B | $0.04B | 5.08 |
| 2008-12-31 | $0.21B | $0.04B | 4.78 |
| 2008-09-30 | $0.23B | $0.04B | 5.21 |
| 2008-06-30 | $0.25B | $0.05B | 5.03 |
| 2008-03-31 | $0.27B | $0.05B | 5.40 |
| 2007-12-31 | $0.13B | $0.06B | 2.42 |
| 2007-09-30 | $0.14B | $0.06B | 2.53 |
| 2007-06-30 | $0.16B | $0.06B | 2.62 |
| 2007-03-31 | $0.19B | $0.06B | 3.03 |
| 2006-12-31 | $0.21B | $0.06B | 3.48 |
| 2006-09-30 | $0.23B | $0.06B | 4.15 |
| 2006-06-30 | $0.25B | $0.05B | 4.58 |
| 2006-03-31 | $0.27B | $0.05B | 5.03 |
| 2005-12-31 | $0.17B | $0.05B | 3.46 |
| 2005-09-30 | $0.18B | $0.04B | 4.38 |
| 2005-06-30 | $0.21B | $0.04B | 5.56 |
| 2005-03-31 | $0.24B | $0.04B | 6.62 |
| 2004-12-31 | $0.26B | $0.03B | 7.79 |
| 2004-09-30 | $0.18B | $0.03B | 5.47 |
| 2004-06-30 | $0.00B | 0.00 | |
| 2004-03-31 | $0.00B | 0.00 | |
| 2003-09-30 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.660B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $967.005B | 46.51 |
| Johnson & Johnson (JNJ) | United States | $470.415B | 18.81 |
| AbbVie (ABBV) | United States | $410.546B | 24.58 |
| Roche Holding AG (RHHBY) | Switzerland | $289.653B | 0.00 |
| Novartis AG (NVS) | Switzerland | $278.650B | 14.77 |
| Merck (MRK) | United States | $230.654B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $219.499B | 12.87 |
| Pfizer (PFE) | United States | $146.634B | 8.06 |
| Sanofi (SNY) | France | $128.522B | 12.34 |
| Bayer (BAYRY) | Germany | $33.795B | 5.93 |